New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Theriva Biologics, Inc.

Contributing Author

Recent Articles by Theriva Biologics, Inc.

Mar-23	Theriva Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma TOVX +8.42% GlobeNewswire
Mar-12	Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
Feb-18	Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications TOVX +6.25% GlobeNewswire
Feb-03	Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 TOVX GlobeNewswire
Dec-29	Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) TOVX GlobeNewswire
Nov-12	Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results TOVX +8.05% GlobeNewswire
Oct-24	Theriva Biologics Provides Response to Unusual Market Action TOVX -5.04% TOVX GlobeNewswire
Oct-16	Theriva Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds TOVX -48.68% GlobeNewswire
Oct-13	Theriva Biologics Announces Upcoming Presentations at Medical Meetings TOVX GlobeNewswire
Oct-06	Theriva Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) TOVX GlobeNewswire
Aug-11	Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results TOVX +14.02% GlobeNewswire
May-27	Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer TOVX -5.49% GlobeNewswire
May-14	Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
May-08	Theriva Biologics Announces Closing of $7.5 Million Public Offering TOVX -20.59% TOVX -17.62% GlobeNewswire
May-07	Theriva Biologics Announces Pricing of $7.5 Million Public Offering TOVX -40.44% GlobeNewswire
May-07	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients TOVX -40.44% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)